Albany NY, United States: According to the report, the global HER2 breast cancer test market was valued at US$ 313.4 Mn in 2020 and is projected to expand at a CAGR of 6.5% from 2021 to 2031.
Albany NY, United States: According to the report, the global HER2 breast cancer test market was valued at US$ 313.4 Mn in 2020 and is projected to expand at a CAGR of 6.5% from 2021 to 2031. HER2 stands for human epidermal growth factor receptor 2. It is involved in normal cell growth. Women newly detected with invasive breast cancers should be tested for HER2. The purpose of HER2 testing is to define whether cancer cells have too many copies of the HER2 gene or cancer cells are in developed stage. Cancers with higher-than-normal levels of HER2 are called HER2-positive. Cancers with normal HER2 levels are called HER2-negative.
Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83844
HER2 status is usually determined using immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). IHC assesses the expression of the HER2 protein in cell membranes and FISH assesses HER2 gene amplification. Immunohistochemistry (IHC) is the common application of immunostaining. It includes the process of selectively isolating antigens (proteins) in cells of a tissue section by using the principle of antibodies binding specifically to antigens in biological tissues. Fluorescence in situ hybridization (FISH) is a laboratory technique to identify and locate a specific DNA sequence on a chromosome.
Increase in Incidence Breast Cancer Worldwide
Rise in prevalence of breast cancer across the globe is projected to drive the global HER2 breast cancer test market during the forecast period. Breast cancer in women is a major health burden globally. According to the World Health Organization (WHO), in 2020, there were 2.3 million women diagnosed with breast cancer, with 685,000 deaths globally. As of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past five years, making it the world’s most prevalent cancer. Significant disability-adjusted life years (DALYs) are lost by women to breast cancer globally than any other type of cancer.
Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=83844
Breast cancer management can be highly effective, particularly when the disease is identified early. Treatment of breast cancer often consists of a combination of surgical removal, radiation therapy, and medication (hormonal therapy, chemotherapy and/or targeted biological therapy) to treat microscopic cancer that has spread from the breast tumor through the blood. The treatment inhibits cancer growth and spread.
Increase in Number of Immunohistochemistry (IHC) Tests
In terms of test type, the global HER2 breast cancer test market has been bifurcated into immunohistochemistry (IHC) and fluorescence/chromogenic in situ hybridization (FISH/CISH). The immunohistochemistry (IHC) segment was valued at US$ 210.6 Mn in 2020 and is projected to reach US$ 413.5 Mn by 2031, expanding at a CAGR of 6.3% from 2021 to 2031. Increase in number of immunohistochemistry (IHC) tests in emerging countries fuels the growth of the segment. Immunohistochemistry (IHC) is used in histology to detect the presence of a specific protein marker that can assist with accurate tumor classification and diagnosis.
Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=83844
Rise in Early Detection Tests Available at Hospitals
In terms of end-user, the global HER2 breast cancer test market has been divided into hospitals and diagnostic laboratories. The hospitals segment accounted for 47.8% share of the market in 2020. The segment is likely to gain market share to reach US$ 523.9 Mn in 2031. Rise in prevalence of breast cancer and early detection tests available in hospitals are projected to propel the global HER2 breast cancer test market during the forecast period.
Increase in the number of cancer treatment hospitals and research institutes across the globe is anticipated to drive the global HER2 breast cancer test market in the near future.
Europe to Lead HER2 Breast Cancer Test Market
The global HER2 breast cancer test market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The HER2 breast cancer test market in Europe was valued at US$ 106.1 Mn in 2020 and is expected to reach US$ 207.2 Mn by 2031, expanding at a CAGR of 6.3% from 2021 to 2031.
The HER2 breast cancer test market in Europe is driven by increase in incidence of breast cancer. According to the European Cancer Information System (ECIS), breast cancer was the most common cancer among women in 2018, with incidence of 29.2% of all cancers in the European Union (EU-28).
Competition Landscape
The global HER2 breast cancer test market is fragmented due to the presence of a large number of leading players. Key players operating in the global market include Abbott Molecular Inc., Biogenex Laboratories, Inc., Leica Biosystems, Roche, Agilent Technologies, and Mylab, Discovery Solutions Pvt. Ltd.
More Trending Reports by Transparency Market Research:
Breast Cancer Liquid Biopsy Market: A biopsy is a tissue or cell sample taken from any part of the patient’s body and examined in the lab for the detection of cancer. Liquid biopsy offers a real-time approach for the treatment of breast cancer. It is used for the collection and analysis of a sample of blood taken from the patient.
Triple-Negative Breast Cancer Treatment Market: Triple-negative breast cancer (TNBC) doesn’t have estrogen or progesterone receptors and also doesn’t make too much of the HER2 protein. Because the cancer cells lack these proteins, hormone therapy and drugs that target HER2 are not helpful, so chemotherapy (chemo) is the main systemic treatment option. And although TNBC tends to respond well to initial chemo, it tends to come back (recur) more frequently than other breast cancers.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453